NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, today highlighted its broad-spectrum antiviral candidate NV-387 as a potential treatment option for the rapidly expanding Bundibugyo strain Ebola outbreak in Africa. The company noted that there are currently no approved vaccines or therapies specifically targeting this virus strain, underscoring the urgent need for effective interventions. NV-387’s host-targeted antiviral mechanism and oral formulation could offer significant advantages in outbreak settings where treatment delivery and healthcare worker safety are critical. The drug is already being prepared for a Phase II clinical trial in the Democratic Republic of Congo for mpox, which could support near-term regional availability if found effective against Ebola. The full press release can be viewed at https://ibn.fm/aSF5Z.
NanoViricides is a clinical stage company that creates special purpose nanomaterials for antiviral therapy. Its novel nanoviricide class of drug candidates and technology are based on intellectual property from TheraCour Pharma, Inc. The company has a Memorandum of Understanding with TheraCour for developing drugs for all antiviral infections, excluding cancer. The company’s lead drug candidate, NV-387, is a broad-spectrum antiviral being developed for respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, mpox, smallpox, and measles. Another advanced candidate is NV-HHV-1 for shingles. The company is currently focused on advancing NV-387 into Phase II human clinical trials.
The company’s platform technology is based on the TheraCour nanomedicine technology, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license for several drugs targeting human viral diseases, including HIV/AIDS, hepatitis B and C, rabies, herpes simplex, varicella-zoster, influenza, dengue, Japanese encephalitis, West Nile virus, Ebola/Marburg viruses, and certain coronaviruses. The company intends to obtain licenses for RSV, poxviruses, and enteroviruses if initial research is successful. As with all drug development, there can be no assurance that any candidate will show sufficient effectiveness and safety for human clinical development. For the latest news and updates on NNVC, visit the company’s newsroom at https://ibn.fm/NNVC.
